2018
Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015
Egilman AC, Wallach JD, Ross JS, Dhruva SS. Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015. JAMA Internal Medicine 2018, 178: 567-569. PMID: 29340562, PMCID: PMC5876838, DOI: 10.1001/jamainternmed.2017.8016.Peer-Reviewed Original Research
2013
Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis
King M, Essick C, Bearman P, Ross JS. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. The BMJ 2013, 346: f264. PMID: 23372175, PMCID: PMC3623604, DOI: 10.1136/bmj.f264.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsCase-Control StudiesCentral Nervous System StimulantsCyclohexanolsDesvenlafaxine SuccinateDextroamphetamineDrug IndustryGift GivingHealth Care SectorHumansInterprofessional RelationsIsoxazolesMarketing of Health ServicesOrganizational PolicyPaliperidone PalmitatePractice Patterns, Physicians'Psychotropic DrugsPyrimidinesSchools, MedicalUnited StatesConceptsPsychotropic medicationsSubsequent prescribing behaviorPhysician prescribingPsychotropic classesOlder antipsychoticsPrescribing behaviorMAIN OUTCOMEMedicationsMedical schoolsPrescribingPhysiciansAntipsychoticsRestriction policiesDesvenlafaxinePaliperidoneStimulantsUS medical schoolsExposureLonger exposureAntidepressantsCohort